Novavax’s COVID-19-Influenza Combination vaccine faces a clinical hold after a trial participant developed motor neuropathy, pending further investigation by the FDA.
Matt Hoffman
Advertisement
Matt Hoffman, associate editorial director for Contagion, has covered medical news for MJH Life Sciences, Contagion's parent company, since 2017. Follow him on Twitter @byMattHoffman or email him at mhoffman @neurologylive.com
Articles by Matt Hoffman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
